Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

What happened

Emergent BioSolutions reported 2026-quarter revenue of $110M and a net loss of $32.7M, compared with $231.1M in revenue and $51.2M in net income a year earlier. Diluted loss per share was $0.64, versus earnings per share of $0.91.

Confirmed

Global impact / market context

The sharp revenue decline and move from profit to loss indicate weaker sales and earnings. Lower NARCAN sales, timing-related product declines, and reduced research contracts may constrain cash available, while the workforce reduction is intended to lower costs as the company completes restructuring.

Analyst inference

The article describes weakness across several revenue sources: nine-month commercial product sales fell 26%, medical countermeasure sales fell 8%, and services revenue fell 8%. Lower NARCAN volumes and pricing mix, plus reduced research activity, point to broad operating pressure rather than one isolated product issue.

Confirmed

What to watch

1. Check whether subsequent quarterly revenue and earnings improve from the reported $110M and net loss, and whether lower NARCAN sales and product timing continue to weigh on results. Analyst inference
2. Watch for completion of the August workforce restructuring in the fourth quarter of 2026 and evidence that the planned cost reductions offset weaker revenue. Confirmed
3. Track whether medical countermeasure sales recover as timing-related CYFENDUS and TEMBEXA sales occur, and whether higher international BAT sales continue partly offsetting declines. Analyst inference

Evidence

• Original source link unavailable